Equities Fixed Income External Managers Private Equity and Real Estate Sustainable Investing


We follow a philosophy that low-turnover, concentrated portfolios derived from sound bottom-up fundamental research provide an opportunity for attractive performance results over time. We have a culture and firm equity ownership structure that help us attract and retain professionals who share those beliefs, and we follow a repeatable investment process that helps us stay true to our philosophy.

Brown Advisory Equity Strategies

Fixed Income

We follow a philosophy that fixed income strategies built from a foundation of stability coupled with fundamental credit research can seek to generate alpha and control risk. We have a culture and firm equity ownership structure that attract and retain professionals who share those beliefs, and we follow a repeatable investment process that helps us stay true to our philosophy.

Brown Advisory Fixed Income Strategies

External Managers

Investment Solutions Group

The Investment Solutions Group is an investment-management team within Brown Advisory that specializes in asset allocation, manager selection, hedge funds and other alternative investment strategies. Dedicated to open-architecture solutions, our team has established a strong track record of identifying high-quality, third-party investment managers across the hedge fund, long-only and private equity universes. We leverage this expertise to help clients assemble portfolios that we believe best fit their needs and goals, offering clients a range of solutions from complete portfolio management to fulfillment of specific hedge-fund and alternative-asset mandates.

Private Equity and Real Estate

Private Equity and Real Estate

Brown Advisory has incorporated private equity and real estate investments in client portfolios since our founding. Today, we can provide that exposure in three distinct ways.

Feeder Funds and Multimanager Funds
We introduce clients to investment opportunities in early- and late-stage venture capital and buyout funds, as well as select real estate funds. We also construct these feeder funds into multimanager funds through our Private Equity Partners (PEP) and Real Estate Partners (REP) vehicles to make private equity investing as easy as possible for our clients.

Customized Private Equity Portfolios
For most clients, private equity is one component of a balanced portfolio that we manage. Other clients, however, come to us specifically for custom-built private equity and real estate portfolios.

Sustainable Investing

Sustainable Investing Strategies

  • Multi-Manager Strategies
  • For clients seeking an open-architecture solution, we have access to several of the premier sustainable managers in the industry - all vetted by internal research.
  • Private Equity
  • Our private equity team is focused on evaluating the growing universe of private impact investments to identify standout opportunities that target various issues of particular concern to our clients. To date, we have placed assets in investments targeting a variety of impact themes such as community impact, microfinance, education technology, sustainable real estate, water initiatives and others.*
  • *Many alternative investments by regulation may only be sold to Accredited Investors (institutions with at least $5 million in assets) or Qualified Purchasers (institutions with at least $25 million in investments).

Customized Portfolios

This diverse assortment of solutions will meet many clients’ sustainability objectives; however, we understand the continued evolution of this space and seek to be able to react quickly to client needs.

For clients with unique missions, value-aligned investing programs, or who simply wish to ensure that they do not own certain controversial companies or have access to certain industries, we offer the following customized options:

Additional Screening: To the extent we have reliable data and can build rules into our compliance systems, we can add specific screens to a separate account to restrict companies (e.g. oil and gas providers) or industries (e.g. tobacco or weaponry).

Customized and Thematic Portfolios: Within a separate account, we can work together to solve for a sustainability need. From a universe of securities researched from both the bottom-up and for their ESG profile, we can assemble a custom portfolio of securities designed to meet many specific sustainable goals or outcomes.

Investment Insights and Thoughts from Brown Advisory
Navigating Our World

NOW 2016 | Gene Editing: Empowering a Cure for Cancer and Other Medical Breakthroughs

Ethan Berkwits
June 23, 2016

Through genetic modification, humans are taking the reins from Mother Nature, making huge strides in fields such as human nutrition and health. Editing genes can help parents with genetic diseases bear healthy babies. Such technology can also lead to the creation of higher-yielding crops and cure cancer with immune cells that are injected into the human body. As our speakers noted, this work also raises the risk of unintended consequences and bears thoughtful consideration by a wide set of stakeholders.

The biggest recent advance accelerating the pace of biotech research is known as CRISPR (clustered regularly interspaced short palindromic repeat), according to Edison Liu, president and CEO of The Jackson Laboratory, which focuses on genomic research. Using CRISPR, scientists target and modify specific genetic sequences in our DNA. By changing the sequences, scientists using CRISPR can accomplish incredible things: cure many genetic diseases, or modify plants to increase production or resistance to disease or pests.

CRISPR has dramatically boosted the efficiency of genetic modification while reducing the cost by about seven times, according to Liu. "This speed, precision and comprehensiveness has never been seen before,” he said. "What is exciting is that the technology has the promise of absolute precision."

Scientists could use CRISPR technology to target human cells that carry mutated genes, such as cells infected with viruses similar to HIV, Liu said. Already, the technology has been used to genetically engineer mosquitoes, proving extremely effective in combating mosquito-borne illnesses, such as malaria. Still, Liu noted the potential negative consequences from annihilating an entire species, even one harmful to humans, such as mosquitoes.

Andrew Hack, chief financial officer at biotech startup Editas Medicine, said his firm plans to use CRISPR technology to perform precise genetic modification to treat a wide variety of human diseases. For example, the company, which raised $100 million in an initial public offering and $120 million in a Series B round led by Bill Gates's advisor, aims through genetic research to find techniques for restoring vision for people who suffer from a form of leber congenital amaurosis (LCA), a disorder of the retina that can lead to severe visual impairment or blindness.

Many of the world’s most devastating diseases—cancer, cystic fibrosis, muscular dystrophy and others—can be traced back to genetic markers and genetic errors. The medical and scientific communities have long struggled to address these root causes, and incredible recent advances in genomics and genetic programming offer new hope to sufferers of conditions once considered incurable. Dr. Edward Liu, CEO of The Jackson Laboratory, one of the world’s leading genomics researchers, is joined by Andrew Hack, M.D., Ph.D., Chief Financial Officer, Editas Medicine, to provide a vision of a future in which we can attack disease at the genetic source—a future that is not as far away as we might imagine.Editas also plans to collaborate with Juno Therapeutics, a leading biopharmaceutical company focused on re-engaging the body's immune system to combat cancer. Editas' mission is to translate its genome editing technology into a new class of drugs that enable precise molecular modification to treat a broad range of diseases at the genetic level.

Liu and Hack said that the ethical challenges posed by editing of human genes is limited to some degree because such activity focuses on somatic cells that will not be passed on to future generations. Indeed, a core aim of gene editing is to treat human diseases without altering the genome, they said. Some scientists believe that current technology could also help parents who are carriers of genetic diseases to have healthy babies.

The public conversation over genetic engineering should focus on the point of view of the patient, Hack said, noting that biomedical companies are devoted to treating patients, not altering genetic fate or changing the genetic traits of future generations.

Liu said the discussion about the future of bioengineering should occur throughout society and not just among scientists. "I don't believe that with powerful tools like this, it can only rest in the hands of scientists," he said. "It has to be a societal discussion and one that has both thoughtful governance as well as controls within the system."


The views expressed are those of the author and Brown Advisory as of the date referenced and are subject to change at any time based on market or other conditions. These views are not intended to be and should not be relied upon as investment advice and are not intended to be a forecast of future events or a guarantee of future results. Past performance is not a guarantee of future performance. The information provided in this material is not intended to be and should not be considered to be a recommendation or suggestion to engage in or refrain from a particular course of action or to make or hold a particular investment or pursue a particular investment strategy, including whether or not to buy, sell, or hold any of the securities mentioned. It should not be assumed that investments in such securities have been or will be profitable. To the extent specific securities are mentioned, they have been selected by the author on an objective basis to illustrate views expressed in the commentary and do not represent all of the securities purchased, sold or recommended for advisory clients. The information contained herein has been prepared from sources believed reliable but is not guaranteed by us as to its timeliness or accuracy, and is not a complete summary or statement of all available data. This piece is intended solely for our clients and prospective clients, is for informational purposes only, and is not individually tailored for or directed to any particular client or prospective client.

This communication and any accompanying documents are confidential and privileged. They are intended for the sole use of the addressee. Any accounting, business or tax advice contained in this communication, including attachments and enclosures, is not intended as a thorough, in-depth analysis of specific issues, nor a substitute for a formal opinion, nor is it sufficient to avoid tax-related penalties